BioCentury
ARTICLE | Clinical News

Infinity drops Hsp90 inhibitor retaspimycin

September 26, 2013 1:11 AM UTC

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) said it will discontinue development of retaspimycin ( IPI-504) after the compound missed the co-primary endpoints in a Phase II trial to treat non-small cell lung cancer (NSCLC). Retaspimycin plus docetaxel did not significantly improve overall survival (OS) in the overall patient population or in a subgroup of patients with squamous cell carcinoma (SCC) vs. placebo plus docetaxel. The double-blind, international trial enrolled 226 docetaxel-naïve patients with second- or third-line NSCLC who had a history of smoking. Retaspimycin is a small molecule heat shock protein 90 (Hsp90) chaperone inhibitor.

Infinity has one remaining compound in its clinical pipeline -- IPI-145, an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta and gamma. Next quarter, Infinity plans to start a Phase III trial with IPI-145 to treat chronic lymphocytic leukemia (CLL). IPI-145 is also in Phase II testing for indolent non-Hodgkin's lymphoma (NHL) and rheumatoid arthritis (RA), as well as Phase IIa testing for allergic asthma. Infinity has exclusive, worldwide rights to IPI-145 from Intellikine Inc., which Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) acquired. ...